Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: In vitro vs in vivo comparison using anacetrapib and dalcetrapib
- 1 September 2015
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 762, 256-262
Abstract
No abstract availableKeywords
Funding Information
- Merck & Co., Inc.
This publication has 27 references indexed in Scilit:
- In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorptionJournal of Lipid Research, 2013
- On- and Off-Target Pharmacology of TorcetrapibDrugs, 2012
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamstersJournal of Lipid Research, 2011
- siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipidsJournal of Lipid Research, 2011
- Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transportJournal of Lipid Research, 2010
- Biochemical characterization of cholesteryl ester transfer protein inhibitorsJournal of Lipid Research, 2010
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or AnacetrapibArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The rabbit as an animal model of hepatic lipase deficiencyBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959